Jefferies Maintains a 'Buy' on ABIOMED (ABMD); Closing In On What Seemed Like Lofty Guidance

Jefferies maintains a 'Buy' on ABIOMED (NASDAQ: ABMD), maintains price target of $25.00.

Jefferies analyst said, "ABMD reported F3Q results ahead of forecasts and delivered a second consecutive Q of profitability on strong Impella adoption. With the full PII data set and economic benefit analysis, recent inclusion into clinical guidelines, and possible expedited Japan approval, the Impella run is just starting."

Jefferies raises FY12 EPS estimate from $0.32 to $0.38 and FY13 from $0.49 to $0.50.

For an analyst ratings summary and ratings history on ABIOMED click here. For more ratings news on ABIOMED click here.

Shares of ABIOMED closed at $20.98 yesterday, with a 52 week range of $9.98-$21.92.

---

Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!

You May Also Be Interested In

• Nomura Securities Sees Trends Continuing To Be Difficult at Wet Seal, Inc. (WTSLA); Cutting FY12/13 Estimates
• UBS Raises Price Target and Estimates on Williams-Sonoma (WSM); Positive Momentum Is Beginning To Pick Up
• Barclays Maintains an 'Overweight' on Avago Technologies (AVGO); Prepped and Ready for iPhone 5

Create E-mail Alert Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter